Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Pioglitazone
Drug ID BADD_D01777
Description Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus.[L11416,L11419,L11422,L11425] It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert _in vivo_ with little consequence.[L11416] The thiazolidinedione class of medications, which also includes [rosiglitazone] and [troglitazone], exerts its pharmacological effect primarily by promoting insulin sensitivity and the improved uptake of blood glucose[L11416] via agonism at the peroxisome proliferator-activated receptor-gamma (PPARγ).[A19757] PPARs are ligand-activated transcription factors that are involved in the expression of more than 100 genes and affect numerous metabolic processes, most notably lipid and glucose homeostasis.[A19759] Thiazolidinediones, including pioglitazone, have fallen out of favor in recent years due to the presence of multiple adverse effects and warnings regarding their use (e.g. congestive heart failure, bladder cancer) and the availability of safer and more effective alternatives for patients with type 2 diabetes mellitus.[L11461]
Indications and Usage Pioglitazone is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [FDA Label].
Marketing Status Prescription
ATC Code A10BG03
DrugBank ID DB01132
KEGG ID D08378
MeSH ID D000077205
PubChem ID 4829
TTD Drug ID D03OFF
NDC Product Code 57237-219; 68071-4964; 50090-2390; 70771-1021; 68071-4959; 50090-4605; 50090-4556; 61919-781; 50090-4780; 50090-2401; 68071-2264; 11532-0011; 68071-2373; 0781-5420; 71335-1298; 68382-306; 70518-2609; 43547-427; 64764-451; 71335-1137; 68071-5155; 68382-307; 60687-391; 33342-056; 57237-221; 72189-293; 68788-7514; 0093-7273; 50090-4586; 70771-1022; 71335-1385; 33342-055; 50090-1321; 68382-308; 16729-020; 70518-2129; 64764-151; 16729-022; 68071-1621; 68788-7511; 0093-7271; 53002-2757; 16729-021; 68071-2437; 70518-2431; 68788-7989; 33342-054; 71335-1659; 0093-7272; 71335-1333; 53002-2755; 71335-0088; 72189-105; 0781-5422; 71335-1759; 70771-1023; 43547-428; 53002-2756; 11532-0013; 68071-5080; 0904-7096; 64764-301; 71610-495; 0904-7090; 70934-619; 0781-5421; 68071-2495; 11532-0012; 57237-220; 43547-426
Synonyms Pioglitazone | 5-(4-(2-(5-Ethyl-2-pyridyl)ethoxy)benzyl)-2,4-thiazolidinedione | U 72107A | U72,107A | U-72107A | U72107A | AD 4833 | AD-4833 | AD4833 | Pioglitazone Hydrochloride | Actos
Chemical Information
Molecular Formula C19H20N2O3S
CAS Registry Number 111025-46-8
SMILES CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.001--Not Available
Abdominal pain07.01.05.002--
Abdominal pain upper07.01.05.003--
Acute myocardial infarction24.04.04.001; 02.02.02.001--Not Available
Alanine aminotransferase increased13.03.01.003--
Altered state of consciousness19.07.01.003; 17.02.04.001--Not Available
Anaemia01.03.02.001--
Anaphylactic shock24.06.02.004; 10.01.07.002--Not Available
Angina pectoris24.04.04.002; 02.02.02.002--
Angioedema23.04.01.001; 10.01.05.009--Not Available
Arthralgia15.01.02.001--
Ascites09.01.05.003; 07.07.01.001; 02.05.04.002--
Aspartate aminotransferase increased13.03.01.006--
Asthenia08.01.01.001--Not Available
Back pain15.03.04.005--
Benign prostatic hyperplasia21.04.02.0010.000577%Not Available
Bladder cancer20.03.04.001; 16.08.01.0010.180687%Not Available
Bladder neoplasm20.03.04.002; 16.08.03.0020.001153%Not Available
Blood albumin decreased13.09.01.0010.000384%Not Available
Blood bilirubin increased13.03.01.008--
Blood creatine phosphokinase increased13.04.01.001--
Blood creatinine increased13.13.01.004--
Blood glucose decreased13.02.02.001--Not Available
Blood glucose increased13.02.02.002--Not Available
Blood potassium increased13.11.01.011--Not Available
Blood pressure increased13.14.03.005--Not Available
Blood thyroid stimulating hormone decreased13.10.03.0110.000384%Not Available
Breast feeding26.05.01.001--Not Available
Bronchitis11.01.09.001; 22.07.01.001--
Cardiac arrest02.03.04.001--
The 1th Page    1 2 3 4 5    Next   Last    Total 8 Pages